首页> 外国专利> Gene therapeutic DNA vector based on VTvaf17 gene therapeutic DNA vector, carrying the target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of these target genes, method for its preparation and use, strain Escherichia coli SCS110-AF / VTvaf17-COL1A1, or Escherichia coli SCS110-AF / VTvaf17-COL1A2, or Escherichia coli SCS110-AF / VTvaf17-P4HA1, or Escherichia coli SCS110-AF / VTvaf17-P4ich2, VTvaf17-COL7A1, or Escherichia coli SCS110-AF / VTvaf17-CLCA2, or Escherichia coli SCS110-AF / VTvaf17-ELN, or Escherichia coli SCS110-AF / VTvaf17-PLOD1, carrying a gene therapy DNA vector, method for its production, production method, industrial scale gene therapy DNA vector

Gene therapeutic DNA vector based on VTvaf17 gene therapeutic DNA vector, carrying the target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of these target genes, method for its preparation and use, strain Escherichia coli SCS110-AF / VTvaf17-COL1A1, or Escherichia coli SCS110-AF / VTvaf17-COL1A2, or Escherichia coli SCS110-AF / VTvaf17-P4HA1, or Escherichia coli SCS110-AF / VTvaf17-P4ich2, VTvaf17-COL7A1, or Escherichia coli SCS110-AF / VTvaf17-CLCA2, or Escherichia coli SCS110-AF / VTvaf17-ELN, or Escherichia coli SCS110-AF / VTvaf17-PLOD1, carrying a gene therapy DNA vector, method for its production, production method, industrial scale gene therapy DNA vector

机译：基于VTvaf17基因治疗DNA载体的基因治疗DNA载体，其携带选自基因组的靶基因COL1A1，COL1A2，P4HA1，P4HA2，COL7A1，CLCA2，ELN，PLOD1，以增加这些靶基因的表达水平，其方法制备和使用菌株Escherichia coli SCS110-AF / VTvaf17-COL1A1或Escherichia coli SCS110-AF / VTvaf17-COL1A2或Escherichia coli SCS110-AF / VTvaf17-P4HA1或ESCcher-SCS110-AF / VTvaf2，Evacher17带有基因治疗DNA载体的COL7A1或大肠杆菌SCS110-AF / VTvaf17-CLCA2或大肠杆菌SCS110-AF / VTvaf17-ELN或大肠杆菌SCS110-AF / VTvaf17-PLOD1，其生产方法，生产方法，工业规模基因治疗DNA载体

页面导航

摘要
著录项
相似文献

摘要

A gene therapy DNA vector based on the VTvafl 7 gene therapy DNA vector carrying a target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of this target gene in humans and animals. Moreover, the gene therapy DNA vector VT vaf 17 -COL 1 A 1 or VTvafl7-COLlA2 or VTvafl 7-P4HA1 or VTvafl 7-P4HA2 or VTvafl7-COL7Al or VTvafl7-CLCA2 or VTvafl 7-ELN or VTvafl 7-PLOD 1 has the nucleotide sequence SEQ ID NO. SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8, respectively. The DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals.

机译：基于带有靶基因的VTvafl 7基因治疗DNA载体的基因治疗DNA载体，所述靶基因选自基因COL1A1，COL1A2，P4HA1，P4HA2，COL7A1，CLCA2，ELN，PLOD1，以增加该靶基因在人类中的表达水平和动物。此外，基因治疗DNA载体VT vaf 17 -COL 1 A 1或VTvafl7-COLlA2或VTvafl 7-P4HA1或VTvafl 7-P4HA2或VTvafl7-COL7A1或VTvafl7-CLCA2或VTvafl 7-ELN或VTvafl 7-PLOD 1具有核苷酸序列SEQ ID NO。 SEQ ID No.3或SEQ ID No.4或SEQ ID No.5或SEQ ID No.6或SEQ ID No.7或SEQ ID No.8。该DNA载体不含病毒来源的核苷酸序列，也没有抗生素抗性基因，为将其安全用于人类和动物的基因治疗提供了可能性。

著录项

公开/公告号RU2018147082A

专利类型
公开/公告日2020-06-29

原文格式PDF
申请/专利权人 СЕЛЛ ЭНД ДЖИН ТЕРАПИ ЛТД (GB);ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ ПРОРЫВНЫЕ ИННОВАЦИОННЫЕ ТЕХНОЛОГИИ (RU);
展开▼

申请/专利号RU20180147082
发明设计人 САВЕЛИЕВА НАТАЛИА (AT);
展开▼

申请日2018-12-27
分类号C12N15/12;C12N15/70;C12N1/21;A61K48;C12R1/21;
国家 RU
入库时间 2022-08-21 11:03:07

相似文献

专利
外文文献